LEAP-N Oncology Series: Emerging Treatments and Complex Cancer Care Considerations

---

LIVE

Saturday, June 20, 2026, 7:50 AM - 11:30 PM, Virtual


AAPA Category 1 CME (3.25 hours), ANCC - Nursing Contact Hour(s) (3.25 hours), Pain and Opioid (1.00 hours), Pharmacotherapeutics (3.25 hours)

LEAP-N Oncology Series is designed for healthcare professionals to keep them updated in oncology patient care concepts with a focus on advanced pharmacotherapeutics. This activity will target education to strengthen knowledge in therapy selection, adverse effect management, and risk mitigation, including antimicrobial resistance and opioid use disorder.

1. Review selection of antimicrobial therapy in oncology patients, including considerations for resistance, spectrum of activity, and patient-specific factors.
2. Discuss the use of recently approved and restricted antimicrobials in the management of infections in the cancer population.
3. Analyze updated changes to antimicrobial agents for the management of C difficile infections.
4. Identify pharmacological treatment options and interventional approaches to chronic pain management in oncology patients.
5. Apply strategies to balance effective pain control with the risk of opioid use disorder (OUD) and treatment-related adverse effects.
6. Examining when GLP-1 RA therapy is appropriate in individuals with cancer.

REQUIREMENTS FOR SUCCESSFUL COMPLETION:

To receive Nursing Contact Hours for this activity, the participant must: 

• Create an account in the Professional Education Portal (PEP) and save your Mobile Number to your PEP account if not already done.

• Register for this activity.

• During activity, TEXT your attendance to 1-844-912-1333 and up to 24hrs after the course has ended using the Activity ID provided by the Facilitator during program.

• Complete a participant evaluation in PEP, under the MyCE tab, within 30 consecutive days of the learning activity where you will also have immediate access to your Certificate.

Virtual registration.  If you would like to request information regarding additional space availability for this activity, please contact Asha Demla @ [email protected].

“The virtual link to the live presentation will be available in the View Content tab after you register.”

In support of improving patient care, The University of Texas MD Anderson Cancer Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

The University of Texas MD Anderson Cancer Center designates this live activity will award 4.25 Nursing Contact Hour(s) which includes APRN 4.25 Pharmacotherapeutics credit(s) .

The University of Texas MD Anderson Cancer Center has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 4.25 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

View the accessibility policy for The University of Texas MD Anderson Cancer Center.

 

The University of Texas MD Anderson Cancer Center complies with all requirements of the identified accrediting body  (ACCME, ANCC, ACPE). Disclosure of speakers, faculty members, planning committee members and their commercial relationships will be shared with learners prior to the educational activity.

Mitigation of Relevant Financial Relationships

The University of Texas MD Anderson Cancer Center adheres to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the educational content of a certified continuing education (CE) activity, including faculty, planners, reviewers, are required to disclose all financial relationships with ineligible companies within the prior 24 months. There is no minimum financial threshold. An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used on or by patients. All relevant financial relationships have been mitigated prior to the start of the activity.

Saturday, June 20, 2026